« Back Research in Social and Administrative Pharmacy

Article in Press

Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey

Published online 22 September 2009 Corrected Proof

References 

  1. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff (Millwood). 2005;24(1):195–205
  2. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515–2523
  3. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002;59(2):115–123
  4. Millar H. Management of physical health in schizophrenia: a stepping stone to treatment success. Eur Neuropsychopharmacol. 2008;18(Suppl 2):S121–S128
  5. Skodol AE. Longitudinal course and outcome of personality disorders. Psychiatr Clin North Am. 2008;31(3):495–503
  6. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry. 2008;69(Suppl 3):38–43
  7. Cotter VT. The burden of dementia. Am J Manag Care. 2007;13(Suppl 8):S193–S197
  8. Ostacher MJ, Nierenberg AA, Iosifescu DV, et al. Correlates of subjective and objective burden among caregivers of patients with bipolar disorder. Acta Psychiatr Scand. 2008;118(1):49–56
  9. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35(3):187–191
  10. Katzung BG. Basic & Clinical Pharmacology. 10th ed.. New York: Lange Medical Books/McGraw-Hill. Medical Publishing Division; 2007;
  11. U.S. Food and Drug Administration. Available at: http://www.fda.gov/cder/drug/infopage/antipsychotics/default.htm. Accessed 11.08.08.
  12. Cohen LJ. Looking beyond the formulary budget in cost-benefit analysis. Am J Manag Care. 1997;3(Suppl):S11–S17
  13. Daumit GL, Crum RM, Guallar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003;60(2):121–128
  14. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ. 2005;24(1):1–31
  15. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371–1376
  16. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001;52:503–517
  17. Stahl S. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge, UK: University of Cambridge; 2002;
  18. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci. 2000;25(2):137–153
  19. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr Res. 2001;47(2-3):281–292
  20. Mark TL, Dirani R, Slade E, Russo PA. Access to new medications to treat schizophrenia. J Behav Health Serv Res. 2002;29(1):15–29
  21. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry. 2004;3(1):4
  22. Jano E, Chen H, Johnson ML, Aparasu RR. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv. 2007;58(11):1400
  23. Huskamp HA. Pharmaceutical cost management and access to psychotropic drugs: the U.S. context. Int J Law Psychiatry. 2005;28(5):484–495
  24. Aparasu RR, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv. 2006;57(12):1693
  25. Copeland LA, Zeber JE, Valenstein M, Blow FC. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003;160(10):1817–1822
  26. Domino ME, Swartz MS. Who are the new users of antipsychotic medications?. Psychiatr Serv. 2008;59(5):507–514
  27. Han E, Liu GG. Racial disparities in prescription drug use for mental illness among population in US. J Ment Health Policy Econ. 2005;8(3):131–143
  28. Herbeck DM, West JC, Ruditis I, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv. 2004;55(6):677–684
  29. Jano E, Johnson M, Chen H, Aparasu RR. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin. 2008;24(3):709–716Epub 2008 Jan 25
  30. Kuo TC, Zhao Y, Weir S, Kramer MS, Ash AS. Implications of comorbidity on costs for patients with Alzheimer disease. Med Care. 2008;46(8):839–846
  31. Luo RD, Belleti DA, Tran D, Arcona S, Salen PN. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia. Int J Psychiatry Med. 2002;32(3):261–269
  32. Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv. 2006;57(1):133–136
  33. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004;55(2):151–156
  34. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull. 2003;29(3):531–540
  35. Van Brunt DL, Gibson PJ, Ramsey JL, Obenchain R. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. MedGenMed. 2003;5(3):16
  36. Wysowski DK, Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry. 1989;46(10):929–932
  37. Woods SW, Sullivan MC, Neuse EC, et al. Best practices: racial and ethnic effects on antipsychotic prescribing practices in a community mental health center. Psychiatr Serv. 2003;54(2):177–179
  38. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter?. J Health Soc Behav. 1995;36(1):1–10
  39. Andersen RM. National health surveys and the behavioral model of health services use. Med Care. 2008;46(7):647–653
  40. Agency for Healthcare Research and Quality . MEPS HC-036: 1996-2005 Pooled Estimation File. Rockville, MD: Agency for Healthcare Research and Quality; 2007;
  41. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry. 1999;56(9):848–853
  42. Osborn DP. The poor physical health of people with mental illness. West J Med. 2001;175(5):329–332
  43. Mojtabai R. Unmet need for treatment of major depression in the United States. Psychiatr Serv. 2009;60(3):297–305
  44. Wang PS, Demler O, Olfson M, Pincus HA, Wells KB, Kessler RC. Changing profiles of service sectors used for mental health care in the United States. Am J Psychiatry. 2006;163(7):1187–1198
  45. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–655
  46. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry. 2004;65(Suppl 6):30–44
  47. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44(6):548–556
  48. Zhu B, Kulkarni PM, Stensland MD, Ascher-Svanum H. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Curr Med Res Opin. 2007;23(11):2805–2814
  49. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159(4):567–572
  50. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223Epub 2005 Sep 19
  51. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079–1087

PII: S1551-7411(09)00078-3

doi: 10.1016/j.sapharm.2009.07.001

« Back Research in Social and Administrative Pharmacy

Article in Press

Article Tools